CLINICAL STUDY: HEART FAILURE
Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients
Daniel L. Dries, MD, MPH*,*,
Mark H. Strong, MD*,
Richard S. Cooper, MD and
Mark H. Drazner, MD, MSc*
* Heart Failure Research Group, Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Department of Preventive Medicine and Epidemiology, Loyola University, Maywood, Illinois, USA
Manuscript received February 23, 2002;
revised manuscript received April 3, 2002,
accepted April 17, 2002.
* Reprint requests and correspondence: Dr. Daniel L. Dries, Heart Failure Research Group, Division of Cardiology, Department of Internal Medicine, Room H8.116, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9034, USA.
daniel.dries{at}utsouthwestern.edu
OBJECTIVES: This study was undertaken to determine whether enalapril had comparable efficacy in black and white patients with asymptomatic left ventricular dysfunction (ALVD) in preventing the development of symptomatic heart failure (HF).
BACKGROUND: Recent studies have suggested that black patients with HF due to systolic dysfunction may derive less benefit than white patients with HF when treated with the same medication.
METHODS: This is a post hoc analysis of the 4,054 black and white participants of the Studies of Left Ventricular Dysfunction Prevention Trial.
RESULTS: Randomization to enalapril was associated with a comparable reduction in the relative risk of the development of symptomatic HF in black (relative risk [RR] 0.67, 95% confidence interval [CI] 0.49, 0.92, p = 0.01) and white patients (RR 0.61, 95% CI 0.53, 0.70, p < 0.001). Treatment with enalapril was also associated with a comparable reduction in the risk of the development of HF requiring medical therapy and the composite end point of death or development of HF in black and white patients. Black as compared with white patients with ALVD were at increased risk of the development of symptomatic HF (RR 1.81, 95% CI 1.51, 2.17, p < 0.001) despite adjustment for available measures of disease severity.
CONCLUSIONS: Despite the increased absolute risk in black patients compared with white patients for the progression of ALVD, enalapril was equally efficacious in reducing the risk of progression of ALVD in these two ethnic groups.
|
Abbreviations and Acronyms
| | ACE | | angiotensin-converting enzyme | | ALVD | | asymptomatic left ventricular dysfunction | | BP | | blood pressure | | HF | | heart failure | | LV | | left ventricular | | NYHA | | New York Heart Association | | SOLVD | | Studies of Left Ventricular Dysfunction |
|
This article has been cited by other articles:
|
|
|
|
 
J. E. Williams
They Say It's in the Genes: Decoding Racial Ideology in Genomics
Journal of Contemporary Ethnography,
October 1, 2011;
40(5):
550 - 581.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Johnson
Ethnic Differences in Cardiovascular Drug Response: Potential Contribution of Pharmacogenetics
Circulation,
September 23, 2008;
118(13):
1383 - 1393.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Goldberg and M. Jessup
Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction
Circulation,
June 20, 2006;
113(24):
2851 - 2860.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Barr
The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?
Ann Intern Med,
December 6, 2005;
143(11):
809 - 815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Taylor, J. T. Wright Jr, R. S. Cooper, B. M. Psaty, A. L. Taylor, J. T. Wright Jr, R. S. Cooper, and B. M. Psaty
Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Circulation,
December 6, 2005;
112(23):
3654 - 3666.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J D Newton, H M Blackledge, and I B Squire
Ethnicity and variation in prognosis for patients newly hospitalised for heart failure: a matched historical cohort study
Heart,
December 1, 2005;
91(12):
1545 - 1550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Wright Jr, J. K. Dunn, J. A. Cutler, B. R. Davis, W. C. Cushman, C. E. Ford, L. J. Haywood, F. H. H. Leenen, K. L. Margolis, V. Papademetriou, et al.
Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril
JAMA,
April 6, 2005;
293(13):
1595 - 1608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Smith, M. G. Shlipak, E. P. Havranek, F. A. Masoudi, W. M. McClellan, J. M. Foody, S. S. Rathore, and H. M. Krumholz
Race and Renal Impairment in Heart Failure: Mortality in Blacks Versus Whites
Circulation,
March 15, 2005;
111(10):
1270 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Shelton, P. Velavan, N. P. Nikitin, A. P. Coletta, A. L. Clark, A. S. Rigby, N. Freemantle, and J. G.F. Cleland
Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost-effectiveness study
Eur J Heart Fail,
January 1, 2005;
7(1):
127 - 135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Julius, M. H. Alderman, G. Beevers, B. Dahlof, R. B. Devereux, J. G. Douglas, J. M. Edelman, K. E. Harris, S. E. Kjeldsen, S. Nesbitt, et al.
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study
J. Am. Coll. Cardiol.,
March 17, 2004;
43(6):
1047 - 1055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Rathore, J. M. Foody, Y. Wang, G. L. Smith, J. Herrin, F. A. Masoudi, P. Wolfe, E. P. Havranek, D. L. Ordin, and H. M. Krumholz
Race, Quality of Care, and Outcomes of Elderly Patients Hospitalized With Heart Failure
JAMA,
May 21, 2003;
289(19):
2517 - 2524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The ALLHAT Officers and Coordinators for the ALLHA
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
JAMA,
December 18, 2002;
288(23):
2981 - 2997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
